TOR-101

TOR-101 is a small molecule drug developed by Tornado Therapeutics. It is a next-generation, highly selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), with minimal or no inhibition of mTORC2. This selectivity is designed to improve safety and tolerability compared to earlier mTOR inhibitors (rapalogs) that inhibit both complexes. The drug aims to extend healthspan and delay the onset of age-related diseases, with primary indications in oncology (neoplasms) and viral respiratory tract infections. Preclinical studies have shown an improved safety profile in animal models, supporting its potential as a geroprotective therapy for aging-related conditions[1][2][3][4][5][7].